1. International Partnership for Microbicides New Science, New Hope – Giving Women Power Over AIDS Women’s Policy, Inc. Briefing Zeda Rosenberg, ScD, Chief Executive Officer Washington, DC, December 1, 2010

2. People Living with HIV in 2009 Total: 33.3 million UNAIDS/WHO 2010 Western & Central Europe 820 000 Middle East & North Africa 460 000 Sub-Saharan Africa 22.5 million Eastern Europe & Central Asia 1.4 million South & South-East Asia 4.1 million Oceania 57 000 North America 1.5 million Latin America 1.4 million East Asia 770 000 Caribbean 240 000

3. Women’s Vulnerability to HIV Biological, economic and socio-cultural factors: Male-to-female transmission higher Young women at even greater risk Financial dependence on male partners Inequality of women (exploitation and violence) Cultural practices such as early marriages, intergenerational sex and concurrent partnerships

4. The Face of HIV/AIDS in the US 27% of US AIDS cases women Nearly 90% of new HIV infections among girls ages 13-19 is due to high-risk heterosexual contact Rate of new HIV infections among African-American women higher than all other groups of women in US One in 30 African-American women is HIV-positive Washington, D.C. Washington, D.C. highest AIDS prevalence in the US (~3%)

5. The Face of HIV/AIDS in Africa Female  76% in sub-Saharan Africa Young  Risk of infection highest among women 20-24 years old Married and monogamous  Stable relationships not a haven A mother  Pregnancy complicated by HIV World Bank Photo

6. HIV Prevention – The Global Response

7. From AIDS Treatment to HIV Prevention 1981 1983 1987 1997 First AIDS case reported in the US HIV virus identified ARV “one drug” mono- therapy approved for use Three-drug therapy: HAART. 36 approved drugs for treatment: research continues 2002 Global Fund established 2003 Drug combinations/ reducing pill burden 2006 2010 ARVs in gel and pill effective for HIV prevention PEPFAR launched

8. Prevention  Behavior change  Male and female condoms  STI treatment  Male circumcision  HIV vaccines  Prevention of mother to child transmission  Post-exposure prophylaxis (PEP)  Pre-exposure prophylaxis (PrEP)  Microbicides  ARV treatment  Treatment for opportunistic infections  Basic care Current and Potential HIV/AIDS Interventions Treatment and Care Prevention ARV-basedNon ARV-based

9. Promise of ARV-Based PrEP Proof-of-concept for Truvada® Potential to be used for men and women Uses approved ARV drugs Convenient oral dosing Potential for different dosing strategies Intermittent Monthly injection Can combine more than one ARV in a single product

10. Microbicides in Product Development Free virus Attachment Fusion Reverse Transcription Protein synthesis and assembly Budding Maturation Integration Maraviroc BMS 793 L167, L872, L882 Tenofovir Dapivirine MIV-150 MIV-170 Pyrimidinediones L’644 peptide

11. Promise of ARV-based Microbicides Antiretroviral (ARV)-based microbicides:  Target HIV specifically  Based on the same types of drugs successfully used to treat HIV and prevent mother to child transmission  Can be delivered in a variety of user-friendly forms: vaginal gel, ring, film, others  Potential to be developed as combination products Proof of concept: tenofovir gel

12. Need for Multiple Products & Formulations Different women, different preferences More product choices, more options for protection Impact of adherence on efficacy – product won’t help if women don’t use it Male partners’ opinions and preferences important

13. Vaginal Rings: An Attractive Technology Long-acting Easy to use Flexible ring, can be self-inserted Suitable for developing world Heat-stable Used safely for other purposes Contraceptive and hormone therapy rings Suitable for drug combinations Phase III dapivirine ring program planned 2011

14. Benefiting People, Communities, Countries Promote reproductive health and HIV awareness Empower women through education and counselling Involve men in HIV prevention Encourage HIV testing Strengthen delivery of and access to health services Engage communities, build community advisory boards Provide employment and professional development Building medical research capabilities in geographical areas of need

15. Path to Product Access Regulatory approval process defined by US Food and Drug Administration, other national regulatory bodies PEPFAR, other donors will assist partner countries in preparations for eventual microbicide introduction

16. Current Resource Environment

17. Investments from Industry Non-exclusive, royalty-free licenses to develop, manufacture and distribute compounds as microbicides in developing countries CompoundLicenseYear Mechanism of Action DapivirineTibotec2004 Reverse transcription: Stops virus from copying its genetic material inside human cells DS001 (L-860,167) DS004 (L-860,872) DS005 (L-860,882) Merck 2005Cell Attachment: Prevents virus from attaching to human cells DS003 (BMS-599793)BMS2005Cell Attachment Tenofovir (IPM & CONRAD) Gilead 2006Reverse transcription MaravirocPfizer2008Cell Attachment DS007 (L-000889644)Merck2008Cell Fusion: Prevents virus from entering human cells

18. Past and Current Donors Supporting Microbicide Research Belgium Canada EC Denmark France Germany India Ireland Netherlands Norway South Africa Spain Sweden United Kingdom United States UNFPA World Bank Foundations Bill & Melinda Gates Wellcome Trust Rockefeller

19. US Government Funding for Microbicide Research FY05FY06FY07FY08FY09FY10FY11 Pres. Budget NIH65,82685,69396,413115,495128,670136,353143,855 CDC5,1853,4353,4179000-- USAID29,76039,600 44,63645,000 Total100,771128,728139,430161,031173,670181,353188,855 Source: Data from NIH OAR Trans-NIH AIDS Research Budget FY 2011

20. USAID: Current Status FY 2011 approved for microbicides at USAID FY 2011 approved for microbicides at USAID $51M Senate $45M House USAID microbicide request FY 2012 Up to $65M to support robust pipeline of research Funding, not science, is the primary obstacle to providing these lifesaving products to women

21. Microbicides: Cause for Optimism New generation of microbicides with highly potent ARVs Proof of concept! (tenofovir gel) Multiple mechanisms of action against HIV Single drugs or combinations Longer duration of protection Multiple formulations to give women more options Increased focus on adherence Support from governments, donors, pharma, scientific, advocacy and local communities

22. Women Urgently Need Microbicides “Now we must build upon the CAPRISA trial results and optimize a highly effective and acceptable microbicide for women and others at high risk of HIV infection which could be deployed by PEPFAR and other programs ” Anthony S. Fauci, MD, Director NIH/NIAID September 29, 2010